Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Structure Therapeutics Q3 2026 Results: Net Loss of $145M, Loss Widens

Structure Therapeutics is a large accelerated filer reporting a limited operating history with significant operating losses and four product candidates currently in clinical development: aleniglipron, ACCG-2671, ACCG-3535, and LTSE-2578. As of October 31, 2026, the company had 214,771,065 ordinary shares outstanding and expects to require substantial additional capital to fund future operations.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-144.6-65.6
Net income-144.8-65.7
EPS (diluted, $ a share)$-0.66$-0.37

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: GPCR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Structure Therapeutics Inc.: key numbers

Share price
$18.57Close, Nov 16
Market cap
$3.99B
Shares outstanding
214.77MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Structure Therapeutics Inc.

All →
4:12 PM ET 8-K
Financial Results

Structure Therapeutics Financial Results

Structure Therapeutics reported third quarter 2026 financial results and provided a corporate update on its oral small molecule obesity portfolio, including the enrollment of its Phase 3 ACCOMPLISH program for aleniglipron. The company ended the quarter with $1.2 billion in cash and investments, which is expected to fund operations through 2028. Topline data from the registrational Phase 3 trials are anticipated in the second half of 2028.

“With our Phase 3 ACCOMPLISH program underway, we are advancing aleniglipron toward potential registration while building a broader portfolio of differentiated oral small molecule treatments for chronic weight management.”

Raymond Stevens, Ph.D., Chief Executive Officer of Structure Therapeutics

“We are also advancing our oral small molecule amylin portfolio by progressing the multiple ascending dose clinical trial of ACCG-2671, preparing to initiate a Phase 1 clinical trial of ACCG-3535 and exploring GLP-1 combination approaches.”

Raymond Stevens, Ph.D., Chief Executive Officer of Structure Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.